CeQur closed a $120 million financing round. The Horw, Switzerland-based company plans to use the funds to drive growth and accelerate commercial expansion efforts. It aims to scale commercial teams and outreach initiatives to bring Simplicity, its four-day wearable insulin delivery device, to more healthcare providers and patients managing diabetes.

Simplicity, a wearable, disposable bolus insulin delivery system, was developed as, essentially, a wearable insulin pen. CeQur began a pilot commercial launch for the FDA-cleared and CE-marked device in early 2021. In April 2021, the company raised $115 million to support that launch and scale up manufacturing.

Each patch now replaces up to 12 mealtime injections, equaling more than 1,000 fewer injections annually.